Research on Peruvian Metals Corp. (PER) from Edison
Percheron Therapeutics’ September quarter update and new preclinical collaboration with Invion reinforce its capital-efficient, combination-led development strategy for HMBD-002, its anti-VISTA antibody. The partners will evaluate HMBD-002 alongside INV043, Invion’s lead Photosoft photodynamic ther
View Full ResearchDisclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
